Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations

Marina Scolnik1, Gurkirpal Singh21Secci&oacute;n Reumatolog&iacute;a, Servicio de Cl&iacute;nica M&eacute;dica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Scolnik M, Singh G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/cbb7ec01f6d74d8ca6ad9a9e76137d47
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cbb7ec01f6d74d8ca6ad9a9e76137d47
record_format	dspace
spelling	oai:doaj.org-article:cbb7ec01f6d74d8ca6ad9a9e76137d472021-12-02T06:03:19ZCombination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations1179-156Xhttps://doaj.org/article/cbb7ec01f6d74d8ca6ad9a9e76137d472011-08-01T00:00:00Zhttp://www.dovepress.com/combination-therapy-versus-celecoxib-a-single-selective-cox-2-agent-to-a8016https://doaj.org/toc/1179-156XMarina Scolnik1, Gurkirpal Singh21Secci&oacute;n Reumatolog&iacute;a, Servicio de Cl&iacute;nica M&eacute;dica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, Palo Alto, CA, USAAbstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for treating symptoms of rheumatologic diseases, such as osteoarthritis and rheumatoid arthritis. Knowing their side effects and the way to minimize them is a medical responsibility. To reduce NSAID-related risk, clinicians should choose a gastroprotective strategy. This may include coprescribing a traditional NSAID with a proton pump inhibitor or a high-dose histamine 2-receptor antagonist (H2RA), or using a cyclo-oxygenase (COX)-2 selective inhibitor or a COX-2 with a proton pump inhibitor. Assessing each patient&#39;s risk (cardiovascular and gastrointestinal) is a priority in order to decide the best intervention to minimize toxicity. In this article, we review some of the common interventions for reducing the gastrointestinal side effects of NSAIDs.Keywords: arthritis, osteoarthritis, celecoxib, nonsteroidal anti-inflammatory drugs, gastrointestinal toxicity, cost-effectivenessScolnik MSingh GDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2011, Iss default, Pp 53-62 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Scolnik M Singh G Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
description	Marina Scolnik1, Gurkirpal Singh21Secci&oacute;n Reumatolog&iacute;a, Servicio de Cl&iacute;nica M&eacute;dica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, Palo Alto, CA, USAAbstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for treating symptoms of rheumatologic diseases, such as osteoarthritis and rheumatoid arthritis. Knowing their side effects and the way to minimize them is a medical responsibility. To reduce NSAID-related risk, clinicians should choose a gastroprotective strategy. This may include coprescribing a traditional NSAID with a proton pump inhibitor or a high-dose histamine 2-receptor antagonist (H2RA), or using a cyclo-oxygenase (COX)-2 selective inhibitor or a COX-2 with a proton pump inhibitor. Assessing each patient&#39;s risk (cardiovascular and gastrointestinal) is a priority in order to decide the best intervention to minimize toxicity. In this article, we review some of the common interventions for reducing the gastrointestinal side effects of NSAIDs.Keywords: arthritis, osteoarthritis, celecoxib, nonsteroidal anti-inflammatory drugs, gastrointestinal toxicity, cost-effectiveness
format	article
author	Scolnik M Singh G
author_facet	Scolnik M Singh G
author_sort	Scolnik M
title	Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
title_short	Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
title_full	Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
title_fullStr	Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
title_full_unstemmed	Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
title_sort	combination therapy versus celecoxib, a single selective cox-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/cbb7ec01f6d74d8ca6ad9a9e76137d47
work_keys_str_mv	AT scolnikm combinationtherapyversuscelecoxibasingleselectivecox2agenttoreducegastrointestinaltoxicityinarthriticpatientspatientandcosteffectivenessconsiderations AT singhg combinationtherapyversuscelecoxibasingleselectivecox2agenttoreducegastrointestinaltoxicityinarthriticpatientspatientandcosteffectivenessconsiderations
_version_	1718400138038214656

Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations

Ejemplares similares